Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Cogent Biosciences (COGT) Equity Average (2018 - 2026)

Cogent Biosciences' Equity Average history spans 9 years, with the latest figure at $622.0 million for Q1 2026.

  • Quarterly Equity Average rose 161.75% to $622.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $622.0 million through Mar 2026, up 161.75% year-over-year, with the annual reading at $446.3 million for FY2025, 73.64% up from the prior year.
  • Equity Average came in at $622.0 million for Q1 2026, up from $469.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $622.0 million in Q1 2026 to a low of $187.0 million in Q2 2025.
  • The 5-year median for Equity Average is $285.5 million (2024), against an average of $310.3 million.
  • Year-over-year, Equity Average plummeted 52.99% in 2025 and then skyrocketed 161.75% in 2026.
  • Cogent Biosciences' Equity Average stood at $272.8 million in 2022, then rose by 2.75% to $280.3 million in 2023, then rose by 1.83% to $285.5 million in 2024, then skyrocketed by 64.44% to $469.4 million in 2025, then skyrocketed by 32.51% to $622.0 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Equity Average are $622.0 million (Q1 2026), $469.4 million (Q4 2025), and $228.8 million (Q3 2025).